MCID: PRT096
MIFTS: 54

Peritoneal Mesothelioma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 12 6 15 17 74
Malignant Mesothelioma of Peritoneum 12 74
Advanced Malignant Mesothelioma of Peritoneum 12
Advanced Malignant Peritoneal Mesothelioma 12
Advanced Peritoneal Malignant Mesothelioma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1788
NCIt 51 C8704 C9350
ICD10 34 C45.1

Summaries for Peritoneal Mesothelioma

Disease Ontology : 12 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary : Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to malignant peritoneal mesothelioma and mucinous adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is BAP1 (BRCA1 Associated Protein 1), and among its related pathways/superpathways are Gastric cancer and Cell cycle Role of SCF complex in cell cycle regulation. The drugs Doxorubicin and Ranpirnase have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and pancreas, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 232)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 33.4 BAP1 CDKN2A EGFR MUC1 NF2
2 mucinous adenocarcinoma 30.0 CDKN2A EGFR MUC1
3 cystadenoma 29.9 MUC1 PGR
4 malignant peripheral nerve sheath tumor 29.6 CDKN2A EGFR MUC1 NF2
5 mesothelioma, malignant 29.2 BAP1 CDKN2A MUC1 NF2 THBD WT1
6 benign multicystic peritoneal mesothelioma 12.7
7 benign peritoneal mesothelioma 12.5
8 peritoneal cystic mesothelioma 11.7
9 benign mesothelioma 11.0
10 lymphohistiocytoid mesothelioma 10.4 CDKN2A THBD
11 hepatoid adenocarcinoma 10.3 EGFR MUC1
12 anaplastic oligodendroglioma 10.3 CDKN2A EGFR
13 bile duct adenoma 10.3 CDKN2A MUC1
14 cholangiolocellular carcinoma 10.3 CDKN2A MUC1
15 pleomorphic liposarcoma 10.3 CDKN2A MUC1
16 ischemic fasciitis 10.3 CDKN2A MUC1
17 mucinous bronchioloalveolar adenocarcinoma 10.3 CDKN2A MUC1
18 well-differentiated liposarcoma 10.3 CDKN2A MUC1
19 transitional meningioma 10.3 MUC1 NF2
20 plasmablastic lymphoma 10.3 CDKN2A MUC1
21 fibrous meningioma 10.3 MUC1 NF2
22 basaloid squamous cell carcinoma 10.3 CDKN2A EGFR
23 cervical adenosquamous carcinoma 10.3 CDKN2A EGFR
24 chordoid glioma 10.3 MUC1 NF2
25 optic nerve sheath meningioma 10.3 CDKN2A NF2
26 cornea cancer 10.3 CDKN2A NF2
27 syringoma 10.3 ESR1 MUC1
28 meningeal melanocytoma 10.3 CDKN2A MUC1
29 anaplastic ependymoma 10.2 MUC1 NF2
30 atypical neurofibroma 10.2 CDKN2A NF2
31 rhabdoid meningioma 10.2 BAP1 NF2
32 spindle cell sarcoma 10.2 MUC1 NF2
33 pericardial mesothelioma 10.2 MUC1 THBD
34 vulva cancer 10.2 CDKN2A EGFR
35 endocervical carcinoma 10.2 CDKN2A ESR1
36 spindle cell carcinoma 10.2 MUC1 PGR
37 progesterone-receptor negative breast cancer 10.2 EGFR PGR
38 lobular neoplasia 10.2 ESR1 MUC1
39 breast mucoepidermoid carcinoma 10.2 MUC1 PGR
40 inguinal hernia 10.2
41 adenocarcinoma 10.2
42 pseudomyxoma peritonei 10.2
43 laryngeal disease 10.2 CDKN2A EGFR
44 clear cell meningioma 10.2 MUC1 PGR
45 vulvar dystrophy 10.2 CDKN2A PGR
46 microglandular adenosis 10.2 EGFR PGR
47 bizarre leiomyoma 10.2 CDKN2A PGR
48 optic nerve neoplasm 10.2 CDKN2A NF2
49 oropharynx cancer 10.2 CDKN2A EGFR
50 hidradenocarcinoma 10.2 EGFR ESR1

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:



Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.83 EGFR
2 Decreased viability GR00221-A-1 9.83 CDKN2A EGFR ESR1 LATS2
3 Decreased viability GR00221-A-2 9.83 ESR1 LATS2
4 Decreased viability GR00221-A-3 9.83 CDKN2A
5 Decreased viability GR00221-A-4 9.83 CDKN2A EGFR ESR1 LATS2
6 Decreased viability GR00402-S-2 9.83 CDKN2A EGFR ESR1 LATS2

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 10.21 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
2 cardiovascular system MP:0005385 10.19 BAP1 CDKN2A EGFR ESR1 LATS2 PGR
3 cellular MP:0005384 10.18 BAP1 CDKN2A EGFR ESR1 LATS2 PGR
4 homeostasis/metabolism MP:0005376 10.16 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
5 endocrine/exocrine gland MP:0005379 10.15 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
6 growth/size/body region MP:0005378 10.14 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
7 immune system MP:0005387 10.1 BAP1 CDKN2A EGFR ESR1 NF2 PGR
8 mortality/aging MP:0010768 10.09 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
9 hematopoietic system MP:0005397 10.07 BAP1 CDKN2A EGFR ESR1 PGR THBD
10 integument MP:0010771 10.02 BAP1 CDKN2A EGFR ESR1 NF2 PGR
11 liver/biliary system MP:0005370 10 CDKN2A EGFR ESR1 LATS2 NF2 THBD
12 digestive/alimentary MP:0005381 9.97 BAP1 CDKN2A EGFR ESR1 THBD
13 muscle MP:0005369 9.95 BAP1 CDKN2A EGFR ESR1 LATS2 PGR
14 neoplasm MP:0002006 9.91 BAP1 CDKN2A EGFR ESR1 NF2 PGR
15 no phenotypic analysis MP:0003012 9.87 BAP1 CDKN2A EGFR ESR1 LATS2 PGR
16 normal MP:0002873 9.73 EGFR ESR1 LATS2 PGR THBD WT1
17 reproductive system MP:0005389 9.56 BAP1 CDKN2A EGFR ESR1 NF2 PGR
18 renal/urinary system MP:0005367 9.55 EGFR ESR1 NF2 THBD WT1
19 respiratory system MP:0005388 9.17 BAP1 CDKN2A EGFR ESR1 NF2 THBD

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2 Ranpirnase Investigational Phase 3 196488-72-9
3
Doxil Approved June 1999 Phase 3,Phase 2 31703
4 Anti-Bacterial Agents Phase 3,Phase 2
5 Antibiotics, Antitubercular Phase 3,Phase 2
6 Topoisomerase Inhibitors Phase 3,Phase 2
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
9
Gemcitabine Approved Phase 2 95058-81-4 60750
10
Durvalumab Approved, Investigational Phase 2,Phase 1 1428935-60-7
11
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
12
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
13
leucovorin Approved Phase 2,Phase 1 58-05-9 143 6006
14
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
15
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
16
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 50-18-0, 6055-19-2 2907
17
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
18
Promethazine Approved, Investigational Phase 2 60-87-7 4927
19
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
20
Fluorouracil Approved Phase 2 51-21-8 3385
21
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
22
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
23
Pancrelipase Approved, Investigational Phase 2 53608-75-6
24
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
25
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
26
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
27
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
28
Fludarabine Approved Phase 1, Phase 2,Phase 2 75607-67-9, 21679-14-1 30751
29
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
30
Bevacizumab Approved, Investigational Phase 2 216974-75-3
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
32
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
33
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
34 Immunologic Factors Phase 2,Phase 1
35 Immunosuppressive Agents Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 2,Phase 1
37 Antimetabolites Phase 2,Phase 1
38 Anti-Infective Agents Phase 2,Phase 1
39 Antiviral Agents Phase 2,Phase 1
40 Antibodies, Monoclonal Phase 2,Phase 1
41 Antineoplastic Agents, Immunological Phase 2,Phase 1
42 Immunoglobulins Phase 2,Phase 1
43 Antibodies Phase 2,Phase 1
44 Mitomycins Phase 2
45 Interferon-gamma Phase 2
46 interferons Phase 2,Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
48 Alkylating Agents Phase 2,Phase 1
49 Vitamin B9 Phase 2,Phase 1
50 Vitamin B Complex Phase 2,Phase 1

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
5 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
6 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Unknown status NCT02588781 Phase 2 Pemetrexed
7 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Unknown status NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
8 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
9 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
10 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
11 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Completed NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
12 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
13 Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma Recruiting NCT03644550 Phase 2 LMB-100
14 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
15 Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer Recruiting NCT03907852 Phase 1, Phase 2 TC-210 T Cells;fludarabine;cyclophosphamide
16 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
17 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
18 Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting NCT02399371 Phase 2
19 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2 Mitomycin C
20 Treatment of Malignant Peritoneal Mesothelioma (MESOTIP) Not yet recruiting NCT03875144 Phase 2 Cisplatin;Pemetrexed
21 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
22 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
23 Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Recruiting NCT03608618 Phase 1
24 CAR T Cells in Mesothelin Expressing Cancers Recruiting NCT03054298 Phase 1
25 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
26 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Active, not recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
27 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
28 Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Not yet recruiting NCT03546426 Phase 1 Pembrolizumab;Interleukin-2
29 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Suspended NCT03436732 Phase 1 LMB-100;SEL-110
30 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
31 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
32 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2) Completed NCT03931304
33 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Recruiting NCT01416714
34 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
35 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
36 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
37 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169
38 Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma Not yet recruiting NCT03867578 Not Applicable

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

MalaCards organs/tissues related to Peritoneal Mesothelioma:

42
Ovary, T Cells, Pancreas, Colon, Lymph Node, Testis, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Peritoneal Mesothelioma:

20
The Peritoneum

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 664)
# Title Authors Year
1
Benign Multicystic Peritoneal Mesothelioma (BMPM) as a rare cause of abdominal pain in a young male: case report and review of the literature. ( 30891172 )
2019
2
Malignant Peritoneal Mesothelioma Mimicking Recurrent Diverticulitis. ( 30915265 )
2019
3
Splicing molecular biology and novel therapies in diffuse malignant peritoneal mesothelioma. ( 30612942 )
2019
4
Pretreatment Controlling Nutritional Status Score and Lactate Dehydrogenase as Predictive Markers of Survival in Patients with Malignant Peritoneal Mesothelioma. ( 30663400 )
2019
5
Malignant Peritoneal Mesothelioma: Treatment Options and Survival. ( 30711965 )
2019
6
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. ( 30777124 )
2019
7
Malignant Peritoneal Mesothelioma Without Asbestos Exposure. ( 30834036 )
2019
8
Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma. ( 30863440 )
2019
9
Prognostic Factors of Malignant Peritoneal Mesothelioma Experienced in Japanese Peritoneal Metastasis Center. ( 30914572 )
2019
10
Bilateral diffuse pulmonary infiltrates secondary to malignant peritoneal mesothelioma - A rare clinical presentation. ( 30937282 )
2019
11
The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma. ( 31063993 )
2019
12
Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. ( 30473172 )
2019
13
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. ( 30794891 )
2019
14
Ten-year experience with peritoneal mesothelioma. ( 30941996 )
2019
15
The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. ( 30954350 )
2019
16
Peritoneal mesothelioma mortality in Italy: Spatial analysis and search for asbestos exposure sources. ( 31030080 )
2019
17
Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. ( 31069554 )
2019
18
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. ( 31092657 )
2019
19
Focal Peritoneal Mesothelioma Demonstrated on FDG PET/CT. ( 31107757 )
2019
20
Benign multicystic peritoneal mesothelioma treated with laparoendoscopic single site surgery: a case report and review of the literature. ( 29372166 )
2018
21
Benign Multicystic Peritoneal Mesothelioma in a Male Patient with Previous Wilms' Tumor: A Case Report and Review of the Literature. ( 30155337 )
2018
22
An unusual cause of acute surgical abdomen: benign multicystic peritoneal mesothelioma associated with adenomatous tumor. ( 30534842 )
2018
23
Malignant peritoneal mesothelioma in patients with endometriosis. ( 29794065 )
2018
24
Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma. ( 30132292 )
2018
25
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2018
26
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. ( 29503128 )
2018
27
Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. ( 29506546 )
2018
28
Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites. ( 29577057 )
2018
29
Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis. ( 29643915 )
2018
30
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. ( 29651664 )
2018
31
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. ( 29721724 )
2018
32
Malignant Peritoneal Mesothelioma in the setting of a Ventriculo-Peritoneal Shunt: A novel clinical presentation. ( 29899672 )
2018
33
Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. ( 29915796 )
2018
34
IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma. ( 30031101 )
2018
35
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. ( 30111295 )
2018
36
Malignant Peritoneal Mesothelioma in an Infant With Familial ATM Mutations. ( 30124550 )
2018
37
Malignant Peritoneal Mesothelioma: A Rare Cause of Ascites. ( 30349836 )
2018
38
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. ( 30386115 )
2018
39
ASO Author Reflections: Management of Malignant Peritoneal Mesothelioma. ( 30421065 )
2018
40
Malignant peritoneal mesothelioma: a review. ( 30450291 )
2018
41
Update on the management of malignant peritoneal mesothelioma. ( 30450299 )
2018
42
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. ( 30510965 )
2018
43
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. ( 30581150 )
2018
44
Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. ( 29048219 )
2018
45
Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. ( 29260418 )
2018
46
Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma. ( 29423664 )
2018
47
Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. ( 29431036 )
2018
48
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. ( 29797583 )
2018
49
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. ( 29978366 )
2018
50
Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. ( 30001711 )
2018

Variations for Peritoneal Mesothelioma

ClinVar genetic disease variations for Peritoneal Mesothelioma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MECOM NM_004991.3(MECOM): c.262C> T (p.Pro88Ser) single nucleotide variant Uncertain significance GRCh38 Chromosome 3, 169381300: 169381300
2 MECOM NM_004991.3(MECOM): c.262C> T (p.Pro88Ser) single nucleotide variant Uncertain significance GRCh37 Chromosome 3, 169099088: 169099088
3 LATS1 NM_004690.4(LATS1): c.2636G> A (p.Trp879Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome 6, 149676695: 149676695
4 LATS1 NM_004690.4(LATS1): c.2636G> A (p.Trp879Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome 6, 149997831: 149997831
5 LATS2 NM_014572.3(LATS2): c.2699_2700insC (p.Val901Serfs) insertion Likely pathogenic GRCh38 Chromosome 13, 20979763: 20979764
6 LATS2 NM_014572.3(LATS2): c.2699_2700insC (p.Val901Serfs) insertion Likely pathogenic GRCh37 Chromosome 13, 21553902: 21553903

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

GO Terms for Peritoneal Mesothelioma

Cellular components related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.61 BAP1 CDKN2A EGFR ESR1 LATS2 MUC1
2 nucleus GO:0005634 9.28 BAP1 CDKN2A EGFR ESR1 LATS2 MUC1

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.62 CDKN2A EGFR ESR1 WT1
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.55 CDKN2A EGFR ESR1 PGR WT1
3 cellular response to estradiol stimulus GO:0071392 9.37 EGFR ESR1
4 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.26 CDKN2A LATS2
5 negative regulation of cell-matrix adhesion GO:0001953 8.96 CDKN2A NF2
6 negative regulation of cell proliferation GO:0008285 8.92 BAP1 CDKN2A NF2 WT1

Molecular functions related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 BAP1 CDKN2A EGFR ESR1 LATS2 MUC1
2 steroid binding GO:0005496 9.16 ESR1 PGR
3 nitric-oxide synthase regulator activity GO:0030235 8.62 EGFR ESR1

Sources for Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....